title: Desensitization to chemotherapeutic agents.
authors.affiliation: Allergy/Immunology, University of Tennessee College of Medicine, Germantown, Tenn. Electronic address: phillieberman@hotmail.com.
authors.forename: Phillip
authors.initials: P
authors.lastname: Lieberman
authors.affiliation: Allergy Immunology Training Program, Mastocytosis Center, Brigham and Women's Hospital, Boston, Mass.
authors.forename: Mariana
authors.initials: M
authors.lastname: Castells
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D000707:Anaphylaxis / Q000139:chemically induced / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects* / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000276:immunology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary; D003888:Desensitization, Immunologic / Q000379:methods; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008453:Maytansine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000276:immunology; D008875:Middle Aged; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine